Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 90

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 90
---
 additional shares of Common Stock to the Investor as consideration for entering into the New Keystone Purchase Agreement.

Investigational New Drug Application

In July 2025, CER-1236 received
an FDA Orphan Drug Designation for the treatment of acute myeloid leukemia. In September 2025, the FDA granted Fast Track Designation
to our lead investigational compound, CER-1236 for acute myeloid leukemia, which is in addition to the existing Orphan Drug Designation
for the same compound. The FDA’s Fast Track Designation is designed to accelerate the development and review of therapies for serious
or life-threatening conditions with unmet medical need. The designation provides us with the opportunity for increased FDA interactions,
potential eligibility for priority review, and the ability to submit data on a rolling basis. Further, it also requires us to potentially
provide expanded access to the investigational drug on an as approved basis under pre-specified conditions.

Fifth PIPE Financing

On October 14, 2025, we entered
into the Fifth Securities Purchase Agreement, pursuant to which we agreed to issue and sell up to 9,750 shares of Series E Preferred Stock
for an aggregate purchase price of up to $7 million in one or more closings. On October 16, 2025, we and the requisite buyers party to
the Fifth Securities Purchase Agreement entered into Amendment No. 1 to the Securities Purchase Agreement (the “SPA Amendment”)
to add an additional Buyer (as defined in the Fifth Securities Purchase Agreement) and increase the size of the Initial Closing (as defined
in the Fifth Securities Purchase Agreement) by $500,000 to an aggregate of approximately $2.25 million of gross proceeds and reduce the
size of the Additional Closings (as defined in the Fifth Securities Purchase Agreement) by an offsetting amount. There was no change to
the aggregate amount of up to $7 million of proceeds to be funded pursuant to the Fifth Securities Purchase Agreement upon consummation
of all of the Closings (as defined in the Fifth Securities Purchase Agreement) provided for therein. On October 16, 2025, pursuant to
the Fifth Securities Purchase Agreement, we issued and sold, and the PIPE Investors purchased 3,816 shares of the Series E Preferred Stock
for aggregate proceeds of approximately $2.25 million, paid in cash. Each Additional Closing under the Fifth Securities Purchase Agreement
is subject to a mutual option of the Company and certain PIPE Investors and satisfaction of